Abstract
Urokinase plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibor type 1(PAI-1) have been reported to be correlated with prognosis in breast cancer. Aim To investigate the prognostic importance of PAI-1 Patients and Methods: PAI-1 was measured with ELISA in cytosol routinely used for estrogen-(ER) and progesteron receptor (PgR) analysis in patients not treated with any systemic adjuvan therapy (n = 100). Information on uPA was available for all cases. Results The estimated relapse free survival, median follow up 38 months, was better (p = 0.014) for those with low PAI-1 compared to those with high. The corresponding test for uPA showed similar results (p = 0.012). Multivariate analysis: When analysed separately, uPA and PAI-1 seem to give approximately the same prognostic information in addition to that of lymph node status, tumor size and PgR (p = 0.060 and p = 0.024, respectively). Conclusion PAI-1 is a promising prognostic factor in breast cancer, which should be further investigated. Urokinase plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibor type 1(PAI-1) have been reported to be correlated with prognosis in breast cancer. To investigate the prognostic importance of PAI-1 PAI-1 was measured with ELISA in cytosol routinely used for estrogen-(ER) and progesteron receptor (PgR) analysis in patients not treated with any systemic adjuvan therapy (n = 100). Information on uPA was available for all cases. The estimated relapse free survival, median follow up 38 months, was better (p = 0.014) for those with low PAI-1 compared to those with high. The corresponding test for uPA showed similar results (p = 0.012). Multivariate analysis: When analysed separately, uPA and PAI-1 seem to give approximately the same prognostic information in addition to that of lymph node status, tumor size and PgR (p = 0.060 and p = 0.024, respectively). PAI-1 is a promising prognostic factor in breast cancer, which should be further investigated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
